• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » FDA panel: Novocure’s brain tumor device improves quality of life but not survival rate

FDA panel: Novocure’s brain tumor device improves quality of life but not survival rate

March 16, 2011 By MassDevice staff

glioblastoma

A revolutionary treatment for a deadly form of brain cancer failed to show a significant increase in the overall survivability rate when measured against chemotherapy, according to an FDA reviewers document posted on the agency’s web site.

In reviewer materials released ahead of a March 17 meeting of the FDA’s neurological devices panel, Food & Drug Administration officials questioned claims made by NovoCure, a privately-held Israeli company, which is seeking pre-market approval for its NovoTTF-100A device.

The document said clinical trials of the device, described by the company as a “non-invasive device, consisting of four sets of insulated electrodes attached to an electronic box,” failed to show a significant increase in overall survivability rate when compared to the standard treatment of aggressive chemotherapy.

The one-year survival rate for patients using the NovoTTF devices versus chemotherapy was essentially the same, at 21.9 percent versus 22.1 percent using the FDA’s strict statistical measurements. Adjusted for the protocol set up in NovoCure’s clinical study, survival rate at one year was slightly higher at 27.8 percent, compared to 21.6 percent.

The biggest difference in the treatments came from quality-of-life scores in post-study patient surveys, which showed a significantly higher quality of life using the NovoCure device when compared to chemotherapy. In particular, patents reported significantly fewer instances of sever gastrointestinal distress including, nausea, vomiting, diarrhea, constipation and pain.

The NovoCure device did have a higher incident rate of convulsions, headaches and mental status changes, which the panel said it would ask company officials about during the March 17 review. However, the document did preface that convulsions are “expected in 20-50% of GBM subjects at various stages of their disease” and that the incidence of convulsions in this trial was low compared to other trials.

The FDA hasn’t made its final decision on the company’s PMA, but did ask questions about a post-market study of the device, stipulating that this shouldn’t be “interpreted to mean that FDA has made a decision on the approvability of this PMA device.”

The agency is considering the device as a treatment for glioblastoma “after surgical and radiation options have been exhausted,” according to a note in the Federal Register. Glioblastoma is the most common form of brain tumor and has a low survival rate.

Patients using the device, which resembles a cap of bandages with electrodes attached, are given continuous low-intensity, alternating electric fields directly to the tumor site. Patients undergoing the treatment are expected to continue wearing the device for more than 18 hours a day.
NovoCure was founded in 2000 by Yoram Palti, a former researcher at the Technion-Israel Institute of Technology. The company has been conducting a Phase III clinical trial of the device since June 2009. NovoCure counts New York-based venture capital firm WFD Ventures as a primary investor.

Filed Under: Neuromodulation/Neurostimulation, News Well, Oncology Tagged With: NovoCure

More recent news

  • BD files patent infringement lawsuit against Baxter over infusion pump tech
  • Tandem Diabetes Care subsidiary earns new FDA clearance for insulin infusion set
  • Apreo Health emerges from stealth with positive data for lung scaffold
  • Tivic adds new vagus nerve stim patent
  • Study backs Teleflex stapler for reducing post-op GERD rates

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy